Skip to main content
OTCMKTS:PTCHF

PureTech Health Stock Forecast, Price & News

$5.24
-0.04 (-0.70 %)
(As of 05/14/2021 02:47 PM ET)
Add
Compare
Today's Range
$5.24
$5.24
50-Day Range
$5.22
$5.85
52-Week Range
$2.60
$6.04
Volume359 shs
Average Volume4,466 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PTCHF News and Ratings via Email

Sign-up to receive the latest news and ratings for PureTech Health and its competitors with MarketBeat's FREE daily newsletter.


PureTech Health logo

About PureTech Health

PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for intractable cancers, lymphatic and gastrointestinal, central nervous system disorders, and inflammatory and immunological diseases in the United States. The company offers KarXT targeting muscarinic cholinergic receptors to treat schizophrenia and dementia-related psychosis, as well as pain; a superabsorbent hydrogel technology platform to treat excess weight and other chronic diseases related to the gastrointestinal pathways; a digital therapeutics to treat cognitive dysfunction associated with neurology and psychiatry conditions; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a immunomodulation platform to treat chronic and acute inflammatory disorders. It also provides hematopoietic stem cell based therapies to treat hematologic malignancies; a vocal biomarker technology to monitor and diagnose psychological and physical medical conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate which is in Phase 1 clinical trial to treat lymphedema, and other lymphatic and fibrotic disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has a collaboration with Boehringer Ingelheim to advance immuno-oncology product candidates. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PTCHF
CUSIPN/A
CIKN/A
Phone617 482 2333
Employees300
Year FoundedN/A

Sales & Book Value

Annual SalesN/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1949th out of 2,044 stocks

Biotechnology Industry

137th out of 158 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











PureTech Health (OTCMKTS:PTCHF) Frequently Asked Questions

What stocks does MarketBeat like better than PureTech Health?

Wall Street analysts have given PureTech Health a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but PureTech Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting PureTech Health?

PureTech Health saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 2,600 shares, an increase of 44.4% from the March 31st total of 1,800 shares. Based on an average trading volume of 8,300 shares, the days-to-cover ratio is currently 0.3 days.
View PureTech Health's Short Interest
.

Who are PureTech Health's key executives?

PureTech Health's management team includes the following people:
  • Ms. Daphne Zohar, Founder, CEO & Exec. Director (Age 50, Pay $1.24M)
  • Dr. Bennett M. Shapiro, Co-Founder (Age 81, Pay $95k)
  • Dr. Robert S. Langer Jr., Co-Founder & Non-Exec. Director (Age 72, Pay $245k)
  • Mr. Stephen M. Muniz J.D., COO, Sec. & Exec. Director (Age 51, Pay $874.24k)
  • Dr. Bharatt M. Chowrira, Pres, Chief of Bus. & Strategy and Exec. Director (Age 56)
  • Dr. David R. Elmaleh, Co-Founder & Sr. Advisor (Age 73)
  • Dr. George Farmer Ph.D., Chief Financial Officer
  • Dr. Joseph B. Bolen, Chief Scientific Officer (Age 67)
  • Ms. Allison Mead Talbot, Head of Communications & Investor Relations
  • Mr. Spencer Ball, Sr. VP of HR

Who are some of PureTech Health's key competitors?

What is PureTech Health's stock symbol?

PureTech Health trades on the OTCMKTS under the ticker symbol "PTCHF."

How do I buy shares of PureTech Health?

Shares of PTCHF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PureTech Health's stock price today?

One share of PTCHF stock can currently be purchased for approximately $5.24.

How many employees does PureTech Health have?

PureTech Health employs 300 workers across the globe.

What is PureTech Health's official website?

The official website for PureTech Health is www.puretechhealth.com.

How can I contact PureTech Health?

The company can be reached via phone at 617 482 2333.


This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.